{"title":"The Ethical Standard for End-of-Life Decisions for Unrepresented Patients.","authors":"Matthew Shea","doi":"10.1080/15265161.2024.2416122","DOIUrl":null,"url":null,"abstract":"<p><p>There has been increasing awareness of the medical and moral challenges in the care of unrepresented patients: those who cannot make their own medical decisions, do not have any surrogate decision maker, and have not indicated their treatment preferences. Most discussions have focused on procedural questions such as who should make decisions for these patients. An issue that has not gotten enough attention is the ethical standard that should govern medical decision making. I explore the question of which ethical standard provides better justification for end-of-life decisions for unrepresented patients. Two options are considered: the conventional and less demanding best interest standard, and the novel and more demanding medical futility standard. I explain the similarities and differences between these two standards, examine arguments for and against each one, and suggest that the medical futility standard is ethically superior and should replace the established best interest standard.</p>","PeriodicalId":50962,"journal":{"name":"American Journal of Bioethics","volume":" ","pages":"1-12"},"PeriodicalIF":17.0000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Bioethics","FirstCategoryId":"98","ListUrlMain":"https://doi.org/10.1080/15265161.2024.2416122","RegionNum":1,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ETHICS","Score":null,"Total":0}
引用次数: 0
Abstract
There has been increasing awareness of the medical and moral challenges in the care of unrepresented patients: those who cannot make their own medical decisions, do not have any surrogate decision maker, and have not indicated their treatment preferences. Most discussions have focused on procedural questions such as who should make decisions for these patients. An issue that has not gotten enough attention is the ethical standard that should govern medical decision making. I explore the question of which ethical standard provides better justification for end-of-life decisions for unrepresented patients. Two options are considered: the conventional and less demanding best interest standard, and the novel and more demanding medical futility standard. I explain the similarities and differences between these two standards, examine arguments for and against each one, and suggest that the medical futility standard is ethically superior and should replace the established best interest standard.
期刊介绍:
The American Journal of Bioethics (AJOB) is a renowned global publication focused on bioethics. It tackles pressing ethical challenges in the realm of health sciences.
With a commitment to the original vision of bioethics, AJOB explores the social consequences of advancements in biomedicine. It sparks meaningful discussions that have proved invaluable to a wide range of professionals, including judges, senators, journalists, scholars, and educators.
AJOB covers various areas of interest, such as the ethical implications of clinical research, ensuring access to healthcare services, and the responsible handling of medical records and data.
The journal welcomes contributions in the form of target articles presenting original research, open peer commentaries facilitating a dialogue, book reviews, and responses to open peer commentaries.
By presenting insightful and authoritative content, AJOB continues to shape the field of bioethics and engage diverse stakeholders in crucial conversations about the intersection of medicine, ethics, and society.